Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IUGR-1 growth hormone dose-comparison study in short children born small for gestational age
NL-OMON26748Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 1990
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of somatropin in Small for gestational age (SGA), intrauterine growth restriction (IUGR) and growth disorder (2 arms), sponsored by Novo Nordisk. Primary endpoints: Linear growth, Bone maturation and 2 more. Started Oct 1990; status: active, not recruiting.
02
Drugs
somatropin
03
Conditions
Small for gestational age (SGA)intrauterine growth restriction (IUGR)growth disorder
Beyond the preview
Go deeper on NL-OMON26748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26748.